Literature DB >> 22308550

Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis.

Iara Maria Sequeiros1, Nabil Jarad.   

Abstract

Time until the subsequent exacerbation (PEx) in cystic fibrosis (CF) is a significant health outcome and one of the significant end points in clinical trials. Risk factors associated with shorter time until the next exacerbation (TUNE) have not been reported. This is a prospective study. TUNE was the number of days from the end of intravenous (IV) antibiotic treatment of a PEx until the day of start of IV antibiotics for the following PEx. Factors assessed were age, gender, site of treatment, CF-related diabetes (CFRD), allergic bronchopulmonary aspergillosis (ABPA) and infection with Pseudomonas aeruginosa (PA). In addition, we examined parameters obtained at day 14 of treatment including forced expiratory volume in the first second (FEV1), body mass index, CF respiratory symptom score, C-reactive protein (CRP) and serum cytokines. A total of 170 exacerbations in 58 adult CF patients (27 female), mean (SD) age 25.8 (6.7) years were analysed. When analysing individual variables, patients with lower FEV1, greater symptom score and higher CRP at the end of exacerbation were associated with shorter TUNE. Patients with ABPA and CFRD had a shorter TUNE than those without. When applying multiple regression analysis, factors associated with shorter TUNE were older age and lower day-14 FEV1 values. Shorter periods until the following PEx are expected in older CF patients and those with lower FEV1 at the end of course of treatment. When these risk factors are present, there may be a justification to take therapeutic steps to increase the time until the following PEx.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22308550     DOI: 10.1177/1479972311433575

Source DB:  PubMed          Journal:  Chron Respir Dis        ISSN: 1479-9723            Impact factor:   2.444


  14 in total

Review 1.  Fungal Pathogens in CF Airways: Leave or Treat?

Authors:  A Singh; A Ralhan; C Schwarz; D Hartl; A Hector
Journal:  Mycopathologia       Date:  2017-08-02       Impact factor: 2.574

2.  Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.

Authors:  Sonya L Heltshe; Natalie E West; Donald R VanDevanter; D B Sanders; Valeria V Beckett; Patrick A Flume; Christopher H Goss
Journal:  Contemp Clin Trials       Date:  2017-11-21       Impact factor: 2.226

3.  Treatment and demographic factors affecting time to next pulmonary exacerbation in cystic fibrosis.

Authors:  Donald R VanDevanter; David J Pasta; Michael W Konstan
Journal:  J Cyst Fibros       Date:  2015-03-06       Impact factor: 5.482

4.  Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Authors:  Sonya L Heltshe; Christopher H Goss; Valeria Thompson; Scott D Sagel; Don B Sanders; Bruce C Marshall; Patrick A Flume
Journal:  Thorax       Date:  2015-04-24       Impact factor: 9.139

5.  Serum Iron Level Is Associated with Time to Antibiotics in Cystic Fibrosis.

Authors:  Alex H Gifford; Dana B Dorman; Lisa A Moulton; Jennifer E Helm; Mary M Griffin; Todd A MacKenzie
Journal:  Clin Transl Sci       Date:  2015-12-08       Impact factor: 4.689

6.  IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis.

Authors:  Donald R VanDevanter; Nathan J Morris; Michael W Konstan
Journal:  J Cyst Fibros       Date:  2015-10-23       Impact factor: 5.482

7.  Cystic Fibrosis Related Diabetes: a Unique Challenge in Diabetes Care.

Authors:  Marina Litvin; Schola Nwachukwu
Journal:  Mo Med       Date:  2016 Sep-Oct

8.  Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.

Authors:  John C Lam; Ranjani Somayaji; Michael G Surette; Harvey R Rabin; Michael D Parkins
Journal:  BMC Infect Dis       Date:  2015-03-22       Impact factor: 3.090

9.  Optimising treatment of CF pulmonary exacerbation: a tough nut to crack.

Authors:  Sonya L Heltshe; Christopher H Goss
Journal:  Thorax       Date:  2016-02       Impact factor: 9.102

10.  Candidate markers associated with the probability of future pulmonary exacerbations in cystic fibrosis patients.

Authors:  Gabriella Wojewodka; Juan B De Sanctis; Joanie Bernier; Julie Bérubé; Heather G Ahlgren; Jim Gruber; Jennifer Landry; Larry C Lands; Dao Nguyen; Simon Rousseau; Andrea Benedetti; Elias Matouk; Danuta Radzioch
Journal:  PLoS One       Date:  2014-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.